Latest news with #Adaptimmune
Associated Press
13-05-2025
- Business
- Associated Press
Adaptimmune Reports Q1 Financial Results and Provides Business Update
TECELRA®launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced $4.0 million Tecelra net sales in Q1 2025 Instituting 2025 Tecelra full year sales guidance of $35-$45 million Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated in 2026 Adaptimmune hadTotal Liquidity1of $60 million as of March 31, 2025;call at 8 a.m. EDT today Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reported financial results and provided a business update for the first quarter ended March 31, 2025. Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: 'The launch of Tecelra continues to rapidly accelerate, as evidenced by all launch metrics. In Q4 2024 we invoiced 2 patients, in Q1 2025 we invoiced 6 patients, and in Q2 to-date we have invoiced 8 patients. The shape of the pipeline of patients being tested and apheresed continues to support a robust acceleration of sales in Q2 and the second half of the year, and we continue to experience 100% manufacturing success rates and no payer denials. As a result, we are now providing guidance for 2025 Tecelra sales in the range of $35-$45 million. I'm confident in the team's ability to identify eligible patients, manufacture a personalized engineered T cell treatment and ultimately deliver product, demonstrating that we have built a successful business platform for cell therapies in solid tumors, paving the way for an equally successful lete-cel launch in 2026.' Tecelra launch momentum increasing - first commercial product in Adaptimmune's sarcoma franchise Lete-cel - next product in Adaptimmune's sarcoma franchise Corporate updates Upcoming milestones Financial Results for the three months ended March 31, 2025 Going Concern Our 2024 Annual Report on Form 10-K, which the Company filed on March 24, 2025, disclosed that there is substantial doubt about our ability to continue as a going concern. We are continuing to implement cost reduction measures and explore the strategic options outlined above. Today's Webcast Details A live webcast and replay can be accessed at Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-846-2266 (International). Callers should dial in 5-10 minutes prior to the scheduled start time and simply ask to join the Adaptimmune call. About Adaptimmune Adaptimmune is a fully integrated cell therapy company working to redefine how cancer is treated. With its unique engineered T cell receptor (TCR) platform, the Company is developing personalized medicines designed to target and destroy difficult-to-treat solid tumor cancers and to radically improve the patient's cancer treatment experience. Forward-Looking Statements This release contains 'forward-looking statements' within the meaning of the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements address our expected future business, financial performance, financial condition, as well as the results of operations and often contain words such as 'anticipate' 'believe,' 'expect,' 'may,' 'plan,' 'potential,' 'will,' and similar expressions. Such statements are based only upon current expectations of Adaptimmune. Reliance should not be placed on these forward-looking statements because they involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances. Total Liquidity (a non-GAAP financial measure) Total Liquidity (a non-GAAP financial measure) is the total of cash and cash equivalents and marketable securities (available-for-sale debt securities). Each of these components appears separately in the condensed consolidated balance sheet. The U.S. GAAP financial measure most directly comparable to Total Liquidity is cash and cash equivalents as reported in the condensed consolidated financial statements, which reconciles to Total Liquidity as follows (in thousands): [This table cannot be displayed. Please visit the source.] The Company believes that the presentation of Total Liquidity provides useful information to investors because management reviews Total Liquidity as part of its assessment of overall solvency and liquidity, financial flexibility, capital position and leverage. Condensed Consolidated Statement of Operations (unaudited, in thousands, except per share data) [This table cannot be displayed. Please visit the source.] Condensed Consolidated Balance Sheets (unaudited, in thousands, except share data) [This table cannot be displayed. Please visit the source.] Condensed Consolidated Cash Flow Statement (unaudited, in thousands) [This table cannot be displayed. Please visit the source.] Adaptimmune Contact Investor Relations Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations T : +1 215 825 9310 M : +1 215 460 8920 [email protected] Media Relations Dana Lynch, Senior Director of Corporate Communications M: +1 267 990 1217 [email protected] 1 Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below 2 Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below To view the source version of this press release, please visit
Yahoo
13-05-2025
- Business
- Yahoo
Adaptimmune Reports Q1 Financial Results and Provides Business Update
TECELRA® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced $4.0 million Tecelra net sales in Q1 2025 Instituting 2025 Tecelra full year sales guidance of $35-$45 million Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated in 2026 Adaptimmune had Total Liquidity1 of $60 million as of March 31, 2025; call at 8 a.m. EDT today Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reported financial results and provided a business update for the first quarter ended March 31, 2025. Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "The launch of Tecelra continues to rapidly accelerate, as evidenced by all launch metrics. In Q4 2024 we invoiced 2 patients, in Q1 2025 we invoiced 6 patients, and in Q2 to-date we have invoiced 8 patients. The shape of the pipeline of patients being tested and apheresed continues to support a robust acceleration of sales in Q2 and the second half of the year, and we continue to experience 100% manufacturing success rates and no payer denials. As a result, we are now providing guidance for 2025 Tecelra sales in the range of $35-$45 million. I'm confident in the team's ability to identify eligible patients, manufacture a personalized engineered T cell treatment and ultimately deliver product, demonstrating that we have built a successful business platform for cell therapies in solid tumors, paving the way for an equally successful lete-cel launch in 2026." Tecelra launch momentum increasing - first commercial product in Adaptimmune's sarcoma franchise 28 Authorized Treatment Centers (ATCs) now accepting referrals On track to have the full network of approximately 30 ATCs open by the end of the year Invoiced 2 patients in Q4 2024, 6 in Q1 2025, and 8 in Q2 to-date (as of May 9, 2025) Apheresed 3 patients in Q4 2024, 13 in Q1 2025, and 8 in Q2 to-date (as of May 9, 2025) 100% success rate in manufacturing to date, with no capacity constraints and an average turnaround of 27 days Successful patient access to Tecelra with no payer denials to date Lete-cel - next product in Adaptimmune's sarcoma franchise Pivotal trial met primary endpoint with 42% ORR including 6 complete responses (CTOS 2024) On track to initiate rolling BLA submission in late 2025; approval anticipated in 2026 Lete-cel will more than double the addressable patient population in the sarcoma franchise Launch readiness activities are on track Corporate updates Review of strategic options with TD Cowen in progress Debt principal paydown of $25 million made in Q1 2025 Upcoming milestones Updates on Tecelra launch momentum Initiate rolling BLA for lete-cel to treat synovial sarcoma and MRCLS in Q4 2025 Financial Results for the three months ended March 31, 2025 Cash / liquidity position: As of March 31, 2025, Adaptimmune had cash and cash equivalents of $41.1 million and Total Liquidity2 of $59.6 million, compared to $91.1 million and $151.6 million respectively, as of December 31, 2024. Revenue: Revenue for the three months ended March 31, 2025, was $7.3 million, compared to $5.7 million for the same period in 2024. Revenue has increased primarily due to $4.0 million in product sales following the FDA approval of TECELRA on August 1, 2024. This was offset by a $2.4 million decrease in development revenue due to revenue from Galapagos replacing Genentech revenue and Galapagos generating comparatively lower revenue due to the collaboration being at an earlier stage of progress than the Genentech collaboration was in the first quarter of 2024. Research and development (R&D) expenses: R&D expenses for the three months ended March 31, 2025, were $28.9 million, compared to $35.2 million for the same period in 2024. R&D expenses decreased due to a decrease in the average number of employees engaged in R&D following the restructuring and reprioritization of activities that was announced in November 2024 and a decrease in subcontracted expenditure, offset by a decrease in offsetting reimbursements receivable for R&D tax and expenditure credits. Selling, general and administrative (SG&A) expenses: SG&A expenses for the three months ended March 31, 2025, were $23.3 million, compared to $19.7 million for the equivalent period in 2024. SG&A expenses increased due to restructuring charges for the restructuring program initiated in the fourth quarter of 2024 for which there was no equivalent in the first quarter of 2024 and an increase in accounting, legal and professional fees due to fees relating to business development work, offset by a decrease in share-based compensation expense due to forfeitures arising as a result of the restructuring program. Net loss: Net loss attributable to holders of the Company's ordinary shares for the three months ended March 31, 2025, was a loss of $47.6 million ($0.03 per ordinary share), compared to $48.5 million ($0.03 per ordinary share), for the equivalent period in 2024. Going ConcernOur 2024 Annual Report on Form 10-K, which the Company filed on March 24, 2025, disclosed that there is substantial doubt about our ability to continue as a going concern. We are continuing to implement cost reduction measures and explore the strategic options outlined above. Today's Webcast DetailsA live webcast and replay can be accessed at Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-846-2266 (International). Callers should dial in 5-10 minutes prior to the scheduled start time and simply ask to join the Adaptimmune call. About AdaptimmuneAdaptimmune is a fully integrated cell therapy company working to redefine how cancer is treated. With its unique engineered T cell receptor (TCR) platform, the Company is developing personalized medicines designed to target and destroy difficult-to-treat solid tumor cancers and to radically improve the patient's cancer treatment experience. Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements address our expected future business, financial performance, financial condition, as well as the results of operations and often contain words such as "anticipate" "believe," "expect," "may," "plan," "potential," "will," and similar expressions. Such statements are based only upon current expectations of Adaptimmune. Reliance should not be placed on these forward-looking statements because they involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances. Total Liquidity (a non-GAAP financial measure) Total Liquidity (a non-GAAP financial measure) is the total of cash and cash equivalents and marketable securities (available-for-sale debt securities). Each of these components appears separately in the condensed consolidated balance sheet. The U.S. GAAP financial measure most directly comparable to Total Liquidity is cash and cash equivalents as reported in the condensed consolidated financial statements, which reconciles to Total Liquidity as follows (in thousands): March 31, December 31, 2025 2024Cash and cash equivalents $ 41,054$ 91,139Marketable securities - available-for-sale debt securities18,509 60,466Total Liquidity $ 59,563$ 151,605 The Company believes that the presentation of Total Liquidity provides useful information to investors because management reviews Total Liquidity as part of its assessment of overall solvency and liquidity, financial flexibility, capital position and leverage. Condensed Consolidated Statement of Operations(unaudited, in thousands, except per share data) Three months ended March 31, 2025 2024Revenue: Product revenue, net $ 4,048$ -Development revenue3,237 5,678Total revenue7,285 5,678Operating expenses: Cost of goods sold(879 )-Research and development(28,857 )(35,207 ) Selling, general and administrative(23,282 )(19,732 ) Total operating expenses(53,018 )(54,939 ) Loss from operations(45,733 )(49,261 ) Interest income910 1,345Interest expense(1,881 )-Other income (expense), net(305 )(61 ) Loss before income tax expense(47,009 )(47,977 ) Income tax expense(575 )(526 ) Net loss attributable to ordinary shareholders $ (47,584 ) $ (48,503 ) Net loss per ordinary share Basic and diluted net loss per share $ (0.03 ) $ (0.03 ) Weighted average shares outstanding: Basic and diluted1,542,159,622 1,451,241,661 Condensed Consolidated Balance Sheets(unaudited, in thousands, except share data) March 31, December 31, 2025 2024Assets Current assets Cash and cash equivalents $ 41,054$ 91,139 Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0 18,509 60,466 Accounts receivable, net of allowance for expected credit losses of $0 and $04,382 1,454 Inventory, net11,759 7,320 Other current assets and prepaid expenses27,294 27,790Total current assets102,998 188,169 Restricted cash1,950 2,067Other non-current assets377 629Operating lease right-of-use assets, net of accumulated amortization of $19,080 and $17,75019,217 19,909Property, plant and equipment, net of accumulated depreciation of $70,048 and $51,89329,724 31,309Intangible assets, net of accumulated amortization of $5,819 and $5,5673,806 3,880Total assets $ 158,072$ 245,963 Liabilities and stockholders' equity Current liabilities Accounts payable $ 5,701$ 8,692 Operating lease liabilities, current4,627 4,709 Accrued expenses and other current liabilities24,863 32,919 Restructuring provision3,437 5,911 Deferred revenue, current12,444 12,296Total current liabilities51,072 64,527 Operating lease liabilities, non-current18,668 19,263Deferred revenue, non-current95,979 95,815Borrowings, non-current25,411 50,237Other liabilities, non-current4,371 4,272Total liabilities195,501 234,114 Stockholders' equity Common stock - Ordinary shares par value £0.001, 2,039,252,874 authorized and 1,547,093,808 issued and outstanding (2024: 2,039,252,874 authorized and1,535,653,620 issued and outstanding) 2,099 2,085 Additional paid in capital1,106,455 1,105,653 Accumulated other comprehensive loss(4,412 )(1,902 ) Accumulated deficit(1,141,571 )(1,093,987 ) Total stockholders' equity(37,429 )11,849 Total liabilities and stockholders' equity $ 158,072$ 245,963 Condensed Consolidated Cash Flow Statement(unaudited, in thousands) Three months ended March 31, 2025 2024Cash flows from operating activities Net loss $ (47,584 ) $ (48,503 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation2,291 2,771 Amortization175 59 Share-based compensation expense669 3,102 Unrealized foreign exchange (gains)/losses(396 )305 Accretion of available-for-sale debt securities(431 )(23 ) Other33 (19 ) Changes in operating assets and liabilities: (Increase)/decrease in receivables and other operating assets(1,582 )15,620 Increase in inventories(4,426 )- Decrease in payables and other current liabilities(13,011 )(7,650 ) Decrease in noncurrent assets281 - Increase in borrowings and other non-current liabilities606 - (Decrease)/increase in deferred revenue(3,217 )2,388Net cash used in operating activities(66,592 )(31,950 ) Cash flows from investing activities Acquisition of property, plant and equipment(1,203 )(102 ) Acquisition of intangible assets- (256 ) Maturity, redemption or sale of marketable securities58,440 - Investment in marketable securities(16,090 )- Other7 -Net cash provided by/(used in) investing activities41,154 (358 ) Cash flows from financing activities Repayment of borrowings(25,451 )- Proceeds from issuance of common stock from offerings, net of commissions and issuance costs 122 29,161 Proceeds from exercise of stock options9 74Net cash (used in)/provided by financing activities(25,320 )29,235 Effect of currency exchange rate changes on cash, cash equivalents and restricted cash 556 (416 ) Net decrease in cash, cash equivalents and restricted cash(50,202 )(3,489 ) Cash, cash equivalents and restricted cash at start of period93,206 147,017Cash, cash equivalents and restricted cash at end of period $ 43,004$ 143,528 Adaptimmune Contact Investor RelationsJuli P. Miller, Ph.D. - VP, Corporate Affairs and Investor RelationsT : +1 215 825 9310M : +1 215 460 Media RelationsDana Lynch, Senior Director of Corporate CommunicationsM: +1 267 990 1 Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below2 Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-04-2025
- Health
- Yahoo
New cancer treatment available on NHS described as 'early Christmas present'
A cancer treatment described as 'the best early Christmas present I could've asked for', has been given approval. KIMMTRAK, a treatment for metastatic uveal melanoma, an aggressive form of eye cancer, has been approved by the FDA and NICE. The NHS has fast-tracked the treatment to hundreds of patients across England. Professor Peter Johnson, NHS national clinical director for cancer, said: "This type of melanoma is difficult to treat when it has spread in the body, so it is great news that the NHS can now offer this pioneering treatment, giving people an option that can extend their lives and offer them valuable extra time with their families and friends." Bahija Jallal, chief executive officer of Immunocore, said: "Every year, hundreds of people are diagnosed with metastatic uveal melanoma who, until now, had no approved treatment options. "KIMMTRAK is the first therapy to demonstrate a survival benefit to patients with this disease and we are focused on making KIMMTRAK available as quickly as possible." Elsewhere, Adaptimmune has received a Breakthrough Therapy Designation for lete-cel, a T-cell therapy used to treat synovial sarcoma, a rare form of cancer. Replimune has also secured FDA priority review and a Biologics License Application acceptance for RP1, a treatment for advanced melanoma. Sushil Patel, chief executive officer at Replimune, said: "There are limited treatment options and a significant unmet need for patients with advanced melanoma."
Associated Press
20-03-2025
- Business
- Associated Press
Adaptimmune Provides Q4 and Full Year 2024 Business Update
TECELRA ® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achieved Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026 Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programs At the end of 2024, Adaptimmune had Total Liquidity 1 of $152 million Evaluating all strategic options to maximize shareholder value Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today provided a Q4 and Full Year 2024 business update. Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: '2025 is the year of commercial execution for Tecelra, as we begin to generate value from our promising sarcoma franchise. The launch is going very well and each step in delivering this important medicine: activating our treatment network; identifying biomarker eligible patients; exceptional manufacturing quality and turn-around times, strengthens our sarcoma platform capabilities for both Tecelra and for lete-cel. These results give us confidence in our strategy to build value from our sarcoma franchise and our path to profitability in 2027. In the context of the current capital markets, we are assessing all strategic options to enable us to achieve these goals.' Tecelra launch momentum increasing – the first commercial product in Adaptimmune's sarcoma franchise 20 Authorized Treatment Centers (ATCs) now accepting referrals On track to have the full network of approximately 30 ATCs open by end of 2025 Apheresed 3 patients in 2024 and invoiced 2 with Q4 product revenue of $1.2m Apheresed 10 patients in 2025 to date Successful reimbursement with no denials to date 100% success rate in manufacturing to date with no capacity constraints Lete-cel – the next product in Adaptimmune's sarcoma franchise Pivotal trial met primary endpoint with 42% ORR including 6 complete responses ( CTOS 2024) On track to initiate rolling BLA submission in late 2025; approval anticipated in 2026 Lete-cel will expand the addressable patient population for sarcoma franchise Corporate updates Executed on 29% reduction in headcount in Q1 2025 as part of approximately $300 million in aggregate cost savings over the next four years to enable goal of achieving operating profitability during 2027 Implemented additional cost reduction for the PRAME and CD70 programs. The Company anticipates this will generate an additional $75m to $100m in aggregate cost savings over the next 4 years Engaged TD Cowen to evaluate strategic options for the Company and for all its programs Upcoming milestones Updates on Tecelra Launch momentum (ATCs, number of patients apheresed) Initiate rolling BLA for lete-cel to treat synovial sarcoma and MRCLS in Q4 2025 Going Concern Our 2024 Annual Report on Form 10-K (the 'Annual Report'), which the Company plans to file on Monday, March 24, will disclose that there is substantial doubt about our ability to continue as a going concern. We are continuing to implement cost reduction measures and explore the strategic options outlined above. More information on these topics will be provided on today's webcast and in the Annual Report. Total Liquidity (a non-GAAP financial measure) Total Liquidity (a non-GAAP financial measure) is the total of cash and cash equivalents and marketable securities (available-for-sale debt securities). The U.S. GAAP financial measure most directly comparable to Total Liquidity is cash and cash equivalents, which reconciles to Total Liquidity as follows (in thousands): [This table cannot be displayed. Please visit the source.] The Company believes that the presentation of Total Liquidity provides useful information to investors because management reviews Total Liquidity as part of its assessment of overall solvency and liquidity, financial flexibility, capital position and leverage. Presentations, publications, and awards Adaptimmune had four poster presentations accepted at the upcoming Society for Immunotherapy of Cancer (SITC) Spring Conference (March 12-14, 2025): 'Emerging T-Cell Receptor T-Cell Therapies for Solid Tumors: Differentiating from CAR-T.' Locke et al. 'Long-term survival of patients with advanced/metastatic synovial sarcoma or myxoid/round cell liposarcoma who received afamitresgene autoleucel T-cell receptor T-cell therapy in SPEARHEAD-1.' D'Angelo et al. (TANDEM 2025 encore) 'Translational analyses reveal mechanisms of afami-cel's anti-tumor activity in synovial sarcoma.' Dupont et al. (SITC 2024 encore) 'Primary analysis of the pivotal IGNYTE-ESO trial of letetresgene autoleucel in patients with synovial sarcoma or myxoid/round cell liposarcoma.' D'Angelo et al. (CTOS 2024 encore) Lete-cel MRCLS pilot study 208469 was published in the Journal of Clinical Oncology and 'Melanoma-associated antigen A4: a cancer testis antigen as a target for adoptive T-cell receptor T-cell therapy' has been published in Cancer Treatment Reviews. In December last year, Forbes Magazine named Tecelra as one of the 6 Revolutionary Tech Developments that Define 2024. In March 2025, Adaptimmune was awarded the 2025 Life Sciences PA (Pennsylvania) Patient Impact Award and was recognized as one of Fast Company's Most Innovative Companies of 2025. Both awards recognize companies that are transforming industries and improving lives through groundbreaking innovation. A virtual KOL event featuring Dr. Sandra D'Angelo, M.D. (Memorial Sloan Kettering Cancer Center) was held on November 18, 2024 to discuss the unmet need and current treatment landscape for patients with sarcoma, including synovial sarcoma (SyS) and myxoid/round cell liposarcoma (MRCLS). Replay available: Adaptimmune Virtual KOL Event - LifeSci Events Today's Webcast Details A live webcast and replay can be accessed at Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-846-2266 (International). Callers should dial in 5-10 minutes prior to the scheduled start time and simply ask to join the Adaptimmune call. About Adaptimmune Adaptimmune is an integrated cell therapy company working to redefine how cancer is treated. With its unique engineered T cell receptor (TCR) platform, the Company is developing personalized medicines designed to target and destroy difficult-to-treat solid tumor cancers and to radically improve the patient's cancer treatment experience. Forward-Looking Statements This release contains 'forward-looking statements' within the meaning of the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements address our expected future business, financial performance, financial condition, as well as the results of operations and often contain words such as 'anticipate' 'believe,' 'expect,' 'may,' 'plan,' 'potential,' 'will,' and similar expressions. Such statements are based only upon current expectations of Adaptimmune. Reliance should not be placed on these forward-looking statements because they involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances. Adaptimmune Contact M : +1 215 460 8920 Media Relations M: +1 267 990 1217
